06:32 AM EDT, 07/28/2026 (MT Newswires) -- GSK's (GSK.L) licensor Hansoh Pharmaceutical Group outlined positive results from the late-stage study of its antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, in patients with progressed or relapsed osteosarcoma. The phase III Artemis-011 trial, conducted in China, met its primary endpoint of progression-free survival, according to a Tuesday filing by the British drugmaker. The drug candidate showed significant improvements in progression-free survival, compared with chemotherapy. No new safety issues were identified, and Hansoh will submit the results for regulatory approval in China.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.